

Forms 7 and 8

AUSTRALIA

Patents Act 1952

DECLARATION IN SUPPORT OF A CONVENTION OR NON-CONVENTION
APPLICATION FOR A PATENT OR PATENT OF ADDITION

Name(s) of Applicant(s) In support of the application made by Colorado Biomedical, Inc.

Title for a patent for an invention entitled Antimicrobial Device and Method

Name(s) and address(es) of person(s) making declaration I/We, John B. Newkirk

do solemnly and sincerely declare as follows:-

- 1. I am/we are the applicant(s) for the patent, or authorised by the abovementioned applicant to make this declaration on its behalf.
- 2. The basic application(s) as defined by Section 141 of the Act was/were made in the following country or countries on the following date(s) by the following applicant(s) namely:-

Country, filing date and name of Applicant for the or each basic application in United States of America on 23 November 19 87
by Roger Bayston and Nancy J. Grove
in _____ on _____ 19 _____
by _____

- 3. The said basic application(s) was/were the first application(s) made in a Convention country in respect of the invention the subject of the application

4. The actual inventor(s) of the said invention is/are Roger Bayston

Name(s) and address(es) of the or each actual inventor Nancy J. Grove

- 5. The facts upon which the applicant(s) is/are entitled to make this application are as follows:-
the applicant is the assignee of the individual inventors.

See reverse side of this form for guidance in completing this part

DECLARED at EVERGREEN, Colorado, U.S.A. this 17th day of July 19 90

John B. Newkirk
John B. Newkirk, President



(12) PATENT ABRIDGMENT (11) Document No. AU-B-27258/88
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 635197

- (54) Title
ANTIMICROBIAL DEVICE AND METHOD
- International Patent Classification(s)
(51)⁵ **A61M 005/00 A61K 031/71 A61L 031/00 A61K 031/495**
- (21) Application No. : **27258/88** (22) Application Date : **23.11.88**
- (87) PCT Publication Number : **WO89/04682**
- (30) Priority Data
- (31) Number (32) Date (33) Country
123922 23.11.87 US UNITED STATES OF AMERICA
- (43) Publication Date : **14.06.89**
- (44) Publication Date of Accepted Application : **18.03.93**
- (71) Applicant(s)
COLORADO BIOMEDICAL INCORPORATED
- (72) Inventor(s)
ROGER BAYSTON; NANCY JANE GROVE
- (74) Attorney or Agent
GRIFFITH HACK & CO. , GPO Box 4164, SYDNEY NSW 2001
- (56) Prior Art Documents
AU 597027 68394/87 A61L 27/00
US 4612337
US 4605564

(57) Claim

1. A medical device made from a material capable of being implanted in living tissue and of long indwelling therein, which exhibits persistent antimicrobial activity in use, and comprises:

a body of polymeric material which is capable of being swelled by a swelling agent and which has been subject to such swelling agent which contains completely dissolved therein one or more antimicrobial agents as a solute, said body being contacted by such swelling agent for a sufficient period of time to promote swelling of the body of material to enlarge the normal size and intermolecular spaces therewithin thereby causing diffusion and migration of the solution containing the selected antimicrobial agent(s) into the enlarged intermolecular spaces of the body of material by the action of the swelling agent within the body of material and said solvent being removed from said solute in the matrix of the body of material by evaporation with said solute remaining in the intermolecular spaces of the body of material and after removal of said solvent said body

of material returning substantially to its original size and shape and having substantially normal intermolecular spaces with said antimicrobial agent(s) substantially uniformly deposited therein for subsequent continuous molecular migration to and molecular diffusion through the surfaces to provide persistent antimicrobial activity at the surfaces during use in the human body, said medical device subject to autoclaving prior to use, and said polymeric material and said antimicrobial agent(s) selected so that the rate of continuous molecular migration and molecular diffusion remains the same or is retarded by the effects of autoclaving.

7. A method of infusing antimicrobials into the body of implantable and long in-dwelling medical devices containing a body of elastomer material comprising the steps of:

completely contacting the surfaces of the body of elastomer with a solution comprising a swelling agent as a solvent and at least one antimicrobial agent as a solute dissolved therein, said elastomer and said at least one antimicrobial agent selected so that the rate of diffusion of the antimicrobial agent out of the medical device will remain the same or be retarded by the effects of autoclaving;

maintaining contact between the solution and the surfaces for a sufficient period of time for the solution to completely penetrate and swell and to enlarge the normal intermolecular spaces of the body of material and to diffuse the solution into the enlarged intermolecular spaces provided by the swelling;

evaporating the solvent from the solution and to thereby deposit and retain the antimicrobial agent within the intermolecular spaces of the body of elastomer while causing the body of material to return substantially to its original physical shape and condition with substantially normal intermolecular spaces; and

(11) AU-B-27258/88
(10) 635197

3

rinsing the surfaces of the treated body of material and autoclaving the treated body of material prior to use.

10. An antimicrobial composition capable of being infused into the body of a medical device made of silicone elastomer or the like comprising a swelling agent for the silicone elastomer, a solvent, and solute consisting of rifampin and clindamycin hydrochloride, said swelling agent being chloroform or one of its homologues.

PCT

OPI DATE 14/06/89

APPLN. ID

27258 / 88

AOJP DATE 20/07/89

PCT NUMBER PCT/US88/04102

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁴ : A61M 5/315</p>	<p>A1</p>	<p>(11) International Publication Number: WO 89/ 04682 (43) International Publication Date: 1 June 1989 (01.06.89)</p>
<p>(21) International Application Number: PCT/US88/04102 (22) International Filing Date: 23 November 1988 (23.11.88) (31) Priority Application Number: 123,922 (32) Priority Date: 23 November 1987 (23.11.87) (33) Priority Country: US (71) Applicant: COLORADO BIOMEDICAL INCORPORATED [US/US]; 6851 Highway 73, Evergreen, CO 80439 (US). (71)(72) Applicants and Inventors: BAYSTON, Roger [GB/GB]; Institute of Child Health, University of London, 30 Guilford Street, London WC1N 1EH (GB). GROVE, Nancy, Jane [US/US]; Post Office Box 99, Conifer, CO 80433 (US).</p>		<p>(74) Agent: SCHELLIN, Eric; 2001 Jefferson Davis Highway, Arlington, VA 22202 (US). (81) Designated States: AT (European patent), AU, BE (European patent), BG, BR, CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), NL (European patent), NO, RO, SE (European patent), SU. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>635197</p>
<p>(54) Title: ANTIMICROBIAL DEVICE AND METHOD</p>		
<p>(57) Abstract</p> <p>The invention relates to a method of impregnating silicone medical implants with antibiotics using chloroform as a swelling agent and a solvent for the antibiotic.</p>		



ANTIMICROBIAL DEVICE AND METHODBackground of the Invention

~~This is a continuation-in-part of prior copending application Serial No. 809,235 filed December 16, 1985.~~

5 Implanted medical devices which involve catheters, valves, molded parts, etc., and which must reside totally or partially within the human body for relatively long periods of time have historically been plagued with the problem of infection. Examples of this group of devices
10 include hydrocephalus shunts and central venous catheters. Colonization of bacteria on the interior surfaces of the catheter or other part of the device can produce serious patient problems, including the need to remove and/or
15 replace the implanted device and secondary infective conditions.

 A considerable amount of attention and study has been directed toward attempting to prevent such colonization by the use of antimicrobial agents, such as antibiotics, bound to the surface of the materials employed in such devices.
20 In such attempts the objective has been to produce a sufficient bacteriostatic or bacteriocidal action to prevent colonization.

 These prior attempts have utilized a wide variety of antimicrobial agents, methods for their application and
25 adherence to a wide variety of substrate materials, including silicone elastomers, polytetrafluoroethane, polyesters, polyethylene, and latex rubber.

 Exemplary of the extensive investigation into this problem by researchers are the following publications,
30 which are incorporated herein by reference.

BAYSTON, R., and MILNER, R.D.G., "Antimicrobial Activity of Silicone Rubber Used in Hydrocephalus Shunts, after Impregnation with Antimicrobial Substances" J Clin Pathol 1981, 134:1057-1062.
35 BAYSTON, R., "Effect of Antibiotic Impregnation on the Function of Slit Valves Used to Control Hydrocephalus" Z. Kinderchir. Band 31, Heft 4, December 1980, pp 353-359.



HARVEY, R.A.; GRECO, R.S.: "The noncovalent bonding of antibiotics to a polytetrafluoroethylene benzalkonium graft." Ann surg 194:642-7, 1981.

5 TROOSKIN, STANLEY A., DONETZ, ANTHONY P.; HARVEY, RICHARD A.; and GRECO, RALPH S. "Prevention of catheter sepsis by antibiotic bonding", Surgery, 1984, pp 547-551.

DONETZ, A.P.; HARVEY, R.A.; GRECO, R.S.; stability of antibiotics bound to polytetrafluoroethylene with cationic surfactants. J Clin Microbiol 19:1-3 1984.

10 Therefore, prior attempts have unfortunately not produced the optimum results. The major drawback has been and remains, the antimicrobial activity provided by certain surface treatments is relatively short lived.
15 This observation has supported the theory that the agents and methods used provide only a temporary surface bonding of the selected agent to the device.

In addition, it has not been demonstrated that a surface treated device can be successfully sterilised by
20 known methods without deleteriously affecting the antimicrobial agent or its bond to the surface of the material of which the device is made. That is, subsequent sterilisation of surface bonded agents tends to shorten the time of antimicrobial activity and, in
25 addition, may produce by-products that are harmful to body tissue.

It would be advantageous if at least preferred forms of the present invention provided a method by which antimicrobial agents can be incorporated into a wide
30 variety of commonly used elastomers or the like, so as to provide a relatively longer term of protection against bacterial colonisation on the surface of those materials without accompanying harmful side effects.

It would also be advantageous if at least preferred
35 forms of the present invention provided an article



The present invention also provides a method of infusing antimicrobials into the body of implantable and long in-dwelling medical devices containing a body of elastomer material comprising the steps of:

5 completely contacting the surfaces of the body of elastomer with a solution comprising a swelling agent as a solvent and at least one antimicrobial agent as a solute dissolved therein, said elastomer and said at least one antimicrobial agent selected so that the rate
10 of diffusion of the antimicrobial agent out of the medical device will remain the same or be reduced by the effects of autoclaving;

maintaining contact between the solution and the surfaces for a sufficient period of time for the solution
15 to completely penetrate and swell and to enlarge the normal intermolecular spaces of the body of material and to diffuse the solution into the enlarged intermolecular spaces provided by the swelling;

evaporating the solvent from the solution and to
20 thereby deposit and retain the antimicrobial agent within the intermolecular spaces of the body of elastomer while causing the body of material to return substantially to its original physical shape and condition with substantially normal intermolecular spaces; and

25 rinsing the surfaces of the treated body of material prior to use.

The present invention utilises a swelling agent which
30 (1) is capable of increasing the intermolecular spaces of silicone elastomers or other polymeric materials or latex; and (2) which is capable of dissolving selected antimicrobial agents without substantially chemically altering them under conditions and in a manner to permit the infusion of the antibacterial agents selected into



the swelled material substantially uniformly and in sufficient amounts to provide for a prolonged significant level of antimicrobial activity when the infused material is subsequently implanted in the body. In vitro tests
5 have shown that the present invention provides effective protection against excessive bacterial challenge in silicone elastomer tubing for at least 28 days during which a nutrient solution is perfused at 37° C through the central lumen of the tubing. Tests have also shown
10 that silicone elastomer treated by the methods of the present invention retain antimicrobial activity after at least 20 months of shelf storage.

Detailed Description of Preferred forms of the Invention

In general, the medical device of the present
15 invention comprises a body of substantially homogeneous polymeric material such as silicone elastomer or the like. One or more antimicrobial agent(s) are substantially uniformly dispersed throughout the body of polymeric material and provide a substantially uniform
20 molecular dispersion of the antimicrobial agent(s) within the intermolecular spaces of the body of polymeric material. The body of polymeric material and the antimicrobial agent therein effectively provide a solid solution of molecules of polymeric material and molecules
25 of antimicrobial agent(s) having a concentration such as to cause diffusion of the molecules of the antimicrobial agent(s) toward and through the side surfaces of the body of polymeric material, when in use, for sufficient periods of time to provide effective protection against
30 colonisation after implant in the human body.

The preferred antimicrobials used in the process of the present invention are the following: 1) rifampin which is a semisynthetic antibiotic derivative of rifamycin B (specifically, rifampin is the hydrazone,



3-(4-methyl-1-pereraziny1-iminomethyl)-rifamycin SV.); and
2) clindamycin hydrochloride. These preferred agents are
preferably used in combination as a solute and together
they provide superior penetration and persistent
5 antimicrobial activity in devices treated according to the
present invention with a broad spectrum covering most
strains of gram positive bacteria causing the majority of
infections in medical devices such as a hydrocephalus
shunt. The agents may also be used as a colloidal
10 suspension or emulsion

The method of manufacture of the medical device
comprises subjecting all surfaces of the body of polymeric
material to a solution containing a suitable swelling agent
(solvent), such as hexane, toluene, xylene or preferably
15 chloroform, and the antimicrobial agent(s) (solute) for a
sufficient time to enable penetration and swelling of the
entire body of polymeric material and substantially
homogeneous dispersion of the antimicrobial agent(s)
throughout the body of polymeric material within the
20 enlarged intermolecular spaces thereof. The swelling agent
is thereafter removed by evaporation to reverse swelling
while retaining the antimicrobial agent(s) in a
substantially uniform dispersion in the intermolecular
spaces throughout the body of polymeric material so that
25 the molecules of the antimicrobial agent(s) are essentially
in solid state solution with the molecules of the body of
the polymeric material and will thereafter migrate toward
the surfaces of the body of the polymeric material and
through the surfaces thereof solely by molecular diffusion.
30 After the swelling agent is removed, the device is suitably
sterilized either by ethylene oxide or gamma irradiation or
low temperature steam autoclaving, but preferably in an
autoclave with the device being subjected to steam heat at
a temperature of 250° F and a pressure of 15 psi above
35 atmospheric to obtain the advantageous results hereinafter
described.

One objective is that there should be enough of the
antimicrobial agent(s) to maintain the desired level of
activity for the desired length of time. Another objective

is that there should be insufficient antimicrobial agent(s) to cause toxicity or other deleterious effects to the implant or to its function or to the recipient. In general, the period of risk for infection resulting from an operation to implant a device may vary from the moment of
5 implantation to any time during the life of the device after the operation. Thus, it is advantageous to be able to control the amount and the dispersion of the antimicrobial agent(s) within the matrix of the elastomer.
10 In order to obtain the desired results, the material from which the device is made must be such as to retain the antimicrobial agent in a manner which prevents release of an oversupply of the agent while at the same time providing a continuous, effective supply of the agent at the surface
15 of the device for a sufficient length of time. An effective amount of antimicrobial agent(s) (e.g. 0.1% to 1.0% by weight of each to volume of solvent) is employed dependent upon the size and shape of a particular medical device and upon the kind and wall thicknesses of the
20 selected polymeric material. In the presently preferred embodiments, for a device such as a shunt or a catheter, the amount of antimicrobial agent(s) is preferably about 0.1% to 0.2% by weight of each agent to volume of solvent.

It has been unexpectedly discovered that good
25 retention of satisfactory amounts of the antimicrobial agent(s) can be maintained without adversely affecting antimicrobial activity when the device is sterilized, preferably in an autoclave apparatus, with the body of the polymeric material being subjected to steam heat at a
30 temperature of 250° F and a pressure of 15 psi above atmospheric for approximately 30 minutes; and this sterilization process, though not others, has a beneficial effect on the diffusion characteristics. The temperature, pressure and time may be varied in accordance with size,
35 shape and other characteristics of the device to achieve complete sterilization.

The infusion treatment used herein is carried out in specially made glass impregnation chambers which conform to the shape of the device which has been selected for

infusion processing, at its maximum swelling. These treatment chambers are designed to accommodate the device to be infused. A sufficient quantity of solution is used to provide contact between the solution and all surfaces of the device.

Charging the Material with Antimicrobial Agent

The clean, dry device to be impregnated is submerged in antimicrobial solution and primed so as to expose the interior and exterior surfaces of the device to the solution and to expel all air bubbles. The device is secured in the chamber, because as the silicone rubber device swells in the charging solution, it becomes buoyant and will rise sufficiently to project out of the charging chamber if it is not properly secured.

The processing time starts when the tube is fully submerged. The chamber is covered to minimize the evaporation of the solvent from the charging solution during treatment. The duration of the treatment is about 30 minutes to one hour of contact with the solution, although the swelling itself may be substantially completed in approximately 10 minutes. The charging chamber is checked visually during processing to make sure that the device has remained submerged.

At the end of the processing period the device is carefully removed from the chamber allowing the liquid inside the device to drain into the chamber. The swelled silicone rubber is mechanically vulnerable at this stage and tears easily. Therefore, it must be handled gently. After it has been removed from the charging chamber, the treated device is immediately immersed in an ethyl alcohol bath. This rinse reduces the spotting of the antimicrobial material on the outside of the device as it dries, but does not significantly reduce the level of the antimicrobial activity. The device is then suspended in a vertical position, and permitted to air dry at room temperature (21° C). The device is then allowed to outgas in this position overnight. At room temperature the device will usually have regained its initial size and shape within 10 minutes

after removal from the charging chamber.

5 After outgassing, the treated device is briefly washed in running tap water and rinsed in deionized water. It is again air dried for a short period in a warm dry air oven at a temperature not exceeding 200° F. The treated device is then sterilized by sufficient autoclaving at 250°F for 30 min at 15 psi above atmospheric pressure as previously described. It was discovered as a part of the present invention that autoclaving is not only satisfactory but also provides new and unexpected results in that there is better retention of the antimicrobial agent(s) within the body of polymeric material. After sterilization, the treated device should be stored in the dark at room temperature.

15 The antimicrobial(s) used to impregnate the device are best prepared in solutions immediately before use. Because of the potential light-sensitive nature of the agent(s) and the volatile nature of the solvents, great care must be taken not to expose the solutions to direct sunlight or to store them in solution for any prolonged period prior to use. The solutions are discarded immediately after use.

20 The antimicrobial(s) are stored in a dry form according to the manufacturers' recommendations. Immediately prior to use they are weighed on an analytical balance to give a concentration typically 0.1% or more of each by weight/volume. The solutes are dissolved in an appropriate solvent such as chloroform. Only glass beakers and glass volumetric flasks are used with the solvent-based solutions.

30 Summary of Benefits and Results

In summary, the device is made of silicone elastomer having a size and shape which can be temporarily expanded to enlarge the normal intermolecular spaces to enable penetration of a treatment solution, including a removable expanding agent and antimicrobial agent(s), and which can be subsequently contracted to substantially the normal size and shape and substantially normal molecular structure by removal of the expanding agent, while retaining a substantial quantity of chemically intact antimicrobial

agent(s) within the substantially normal molecular structure.

In use, it is believed that the antimicrobial agent(s) within the body of polymeric material are released to and through the surfaces by solid state diffusion. Because of the molecular structure of the polymer and the intimate molecular association of the antimicrobial agent(s) therewith, the diffusion of these agent(s) occurs at a rate which provides antimicrobial efficacy at the surfaces of the device for a substantial period of time.

Silicone elastomers of varying consistencies and/or configurations, when processed according to the invention, demonstrate the ability to (1) absorb antimicrobials into their intermolecular spaces and retain chemically intact antimicrobials within their intermolecular spaces; (2) release antimicrobials over time through constant diffusion of the antimicrobial to and through their surfaces; (3) retain antimicrobial activity after sterilization; (4) be capable of being sterilized by autoclaving without loss of antimicrobial activity and with enhanced retention of antimicrobials; (5) retain antimicrobial activity over time of storage; (6) provide effective protection against excessively high bacterial challenge; and (7) when processed according to the invention and implanted in living tissues, demonstrate no harmful side effects to surrounding tissue(s) and/or organs.

Thus, surgically implanted silicone elastomer devices such as hydrocephalus shunts, when processed according to the invention, will resist bacterial contamination introduced at the time of surgery which can lead to the colonization of the implant and its ultimate failure, removal and replacement; and will provide a longer period of protection against colonization by introduced bacteria due to the constant diffusion of antimicrobial to the surfaces of the device.

~~It is contemplated that the inventive concepts herein described may be variously otherwise embodied and it is intended that the appended claims be construed to include~~



It is contemplated that the concepts herein described may be variously otherwise embodied and it is intended that alternative embodiments of the invention are included except insofar as limited by the prior art.

RECEIVED

SEP 19 1964

U.S. PATENT OFFICE



THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

~~WHAT IS CLAIMED IS:~~

1. A medical device made from a material capable of being implanted in living tissue and of long indwelling therein, which exhibits persistent antimicrobial activity in use, and comprises:

a body of polymeric material which is capable of being swelled by a swelling agent and which has been subject to such swelling agent which contains completely dissolved therein one or more antimicrobial agents as a solute, said body being contacted by such swelling agent for a sufficient period of time to promote swelling of the body of material to enlarge the normal size and intermolecular spaces therewithin thereby causing diffusion and migration of the solution containing the selected antimicrobial agent(s) into the enlarged intermolecular spaces of the body of material by the action of the swelling agent within the body of material and said solvent being removed from said solute in the matrix of the body of material by evaporation with said solute remaining in the intermolecular spaces of the body of material and after removal of said solvent said body of material returning substantially to its original size and shape and having substantially normal intermolecular spaces with said antimicrobial agent(s) substantially uniformly deposited therein for subsequent continuous molecular migration to and molecular diffusion through the surfaces to provide persistent antimicrobial activity at the surfaces during use in the human body, said medical device subject to autoclaving prior to use, and said polymeric material and said antimicrobial agent(s) selected so that the rate of continuous molecular migration and molecular diffusion remains the same or is retarded by the effects of autoclaving.

2
3
4
5
6
7
8
9
10



2. The medical device of claim 1 wherein:
the selected material is a silicone elastomer.

3. The medical device of claims 1 and 2 wherein:
the swelling agent is chloroform or its chemical homologues.

4. The medical device of claim 3 wherein:
the antimicrobial agent is selected from the group consisting of rifampin, clindamycin hydrochloride and mixtures thereof.

5. The medical device of claim 4 wherein:
each selected antimicrobial is dissolved in the swelling agent in an amount of about 0.1% to 1.0% weight by volume of the swelling agent.

6. The medical device of claim 1 wherein:
said autoclaving occurs at about 250°F and at a pressure of about 15 psi above atmosphere.

7. A method of infusing antimicrobials into the body of implantable and long in-dwelling medical devices containing a body of elastomer material comprising the steps of:
completely contacting the surfaces of the body of elastomer with a solution comprising a swelling agent as a solvent and at least one antimicrobial agent as a solute dissolved therein, said elastomer and said at least one antimicrobial agent selected so that the rate of diffusion of the antimicrobial agent out of the medical device will remain the same or be retarded by the effects of autoclaving;
maintaining contact between the solution and the surfaces for a sufficient period of time for the solution



to completely penetrate and swell and to enlarge the normal intermolecular spaces of the body of material and to diffuse the solution into the enlarged intermolecular spaces provided by the swelling;

evaporating the solvent from the solution and to thereby deposit and retain the antimicrobial agent within the intermolecular spaces of the body of elastomer while causing the body of material to return substantially to its original physical shape and condition with substantially normal intermolecular spaces; and

rinsing the surfaces of the treated body of material and autoclaving the treated body of material prior to use.

8. The method of claim 7 wherein:

the antimicrobial agent is selected from the group of broad spectrum antibiotics consisting of rifampin, clindamycin hydrochloride and mixtures thereof and is dissolved in chloroform.

9. The method of claim 7 and 8 wherein:

said autoclaving occurs at about 250°F and at about 15 psi above atmospheric pressure.

10. An antimicrobial composition capable of being infused into the body of a medical device made of silicone elastomer or the like comprising a swelling agent for the silicone elastomer, a solvent, and solute consisting of rifampin and clindamycin hydrochloride, said swelling agent being chloroform or one of its homologues.

12. A medical device for use in the human body and comprising:

a body of silicone elastomer having a matrix of



polymeric molecules;

two antimicrobial agents substantially uniformly dispersed throughout said body of polymeric material and providing a substantially uniform molecular dispersion of said antimicrobial agents within the normal intermolecular spaces of said body of silicone elastomer; and

said body of silicone elastomer and said antimicrobial agents therein effectively providing a solid solution of molecules of polymeric material and molecules of antimicrobial agent having a concentration and concentration distribution of antimicrobial agent such as to cause solid state diffusion of the molecules of the antimicrobial agent toward and through the intermolecular spaces of the body of polymeric material for a sufficient period of time to provide effective protection against infection after implant in the human body, the rate of said solid diffusion having remained the same or been retarded by autoclaving such device.

13. The invention of claim 12 wherein:

the swelling agent is chloroform or a chemical homologue.

14. The invention of claims 12 and 13 wherein:

the antimicrobial agents are selected from the group consisting of rifampin, clindamycin hydrochloride and mixtures thereof.

15. The invention of claim 14 wherein:

each of the antimicrobial agents are dissolved in chloroform in the amount of 0.1% to 1.0% by weight of agent to volume of chloroform.

cbl\claims



Dated this 11th day of January 1993

COLORADO BIOMEDICAL INCORPORATED

By their Patent Attorneys

GRIFFITH HACK & CO.


0
2
4

6
8

0
2

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US88/04102

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC(4): A61M 5/315		
US C1: 604/265		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	604/265, 266 623/11	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
<u>X</u> <u>Y</u>	US, A, 4,605,564 (KULLA ET AL.) 12 August 1986 See column 2 lines 5-21, column 2 line 37 to column 3 line 6.	<u>1, 2, 7</u> <u>3-6, 8-15</u>
<u>X</u> <u>Y</u>	US, A, 4,612,337 (FOX, JR. ET AL) 16 September 1986 See column 2 lines 36-50, column 2 line 64 to column 3 line 20, column 3 lines 27 to 38, column 3 lines 53 to 60.	<u>1-3, 7, 12, 13</u> <u>4, 5, 8-11, 14-15</u>
<u>X</u> <u>Y</u>	Journal of Clinical Pathology, Volume 134, issued 1981, Bayston et al, "Antimicrobial activity of silicone rubber used in hydrocephalus shunts, after impregnation with antimicrobial substances", pp. 1057-1062 see page 1057 column 2 to page 1058 column 1, page 1060, page 1061.	<u>1-4, 10-14</u> <u>5-9, 15</u>
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"d" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
12 January 1989	10 APR 1989	
International Searching Authority	Signature of Authorized Officer	
ISA/US	 Sharon Rose	